country_alpha_3_code,country,partner_management,partner_management_justification,hbv_screening_for_hbsag,hbv_screening_for_hbsag_justification,vaccination_for_hbv,vaccination_for_hbv_justification,vaccination_for_hpv,vaccination_for_hpv_justification,syphilis_screening,syphilis_screening_justification,ng_screening,ng_screening_justification,ct_screening,ct_screening_justification
ALB,Albania,ERR: yes (REF: no),"ALB HIV Guidelines ENG.pdf: Page 58, Table, Counselling row: 'Assess intimate partner violence and gender based violence.'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, HBsAg row: 'At the beginning. If you vaccinate negatively. If positive, refer to your hepatologist and advise against stopping PrEP due to the risk of inflaming hepatitis.'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, Review vaccinations row: 'First (focus on HBV, HPV, HAV, DT)'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, Review vaccinations row: 'First (focus on HBV, HPV, HAV, DT)'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, VDRL or RPR row: 'First, and repeat every six months.'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, CT/NG row: 'Depending on availability, at the beginning and every 6 months (rectal PCR, tampon and urine).'",yes,"ALB HIV Guidelines ENG.pdf: Page 57, Table 35, CT/NG row: 'Depending on availability, at the beginning and every 6 months (rectal PCR, tampon and urine).'"
AND,Andorra,no,Justification not provided,yes,"AND PrEP Guidelines ENG.pdf: Page 7, Table 1 recommends screening for HBV using 'Anti HBs*, anti HBc and HBsAg serology'.",yes,"AND PrEP Guidelines ENG.pdf: Page 5 states, 'Vaccination against hepatitis A virus (HBV) and hepatitis B (HBV) and against human papillomavirus (HPV), if applicable (with complete regimen by age)'.",yes,"AND PrEP Guidelines ENG.pdf: Page 5 states, 'Vaccination against hepatitis A virus (HBV) and hepatitis B (HBV) and against human papillomavirus (HPV), if applicable (with complete regimen by age)'.",yes,"AND PrEP Guidelines ENG.pdf: Page 6, under 'Analytical determination', lists 'Syphilis' as part of the Sexually transmitted infections (STIs) screenings.",yes,"AND PrEP Guidelines ENG.pdf: Page 6, under 'Analytical determination', lists 'Gonorrhea' as part of the Sexually transmitted infections (STIs) screenings.",yes,"AND PrEP Guidelines ENG.pdf: Page 6, under 'Analytical determination', lists 'Chlamydia' as part of the Sexually transmitted infections (STIs) screenings."
ARG,Argentina,yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 20, under ""Sífilis"": ""En caso de confirmarse infección por sífilis, se recomienda el tratamiento inmediato a la persona y su/s pareja/s de acuerdo a los algoritmos vigentes"". Page 20, under ""Gonorrea y clamidia"": ""Debe realizarse el tratamiento precoz de las personas en quienes se detecte infección por clamidia y gonococo y su/s pareja/s.""",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, ""Diagnóstico y tratamiento inicial de ITS"": ""HBV en individuos no vacunados (incluyendo detección de anticuerpos anti core [HBcAc], antígeno de superficie [HBsAg] y anticuerpos anti antígeno de superficie [HBsAc])"".",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, ""Inmunizaciones"": ""Todas las personas que sean candidatas a PrEP (independientemente de si finalmente la reciben o no) deben recibir inmunización contra HBV y HAV.""",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 9, ""1.9. Educación sexual integral (ESI)"": ""Es recomendable además la vacunación contra el virus del papiloma humano (VPH) en personas menores de 26 años que accedan a servicios de Prevención combinada, independientemente de si resultan elegibles para recibir PrEP.""",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, ""Diagnóstico y tratamiento inicial de ITS"": ""Se recomienda en todos los casos el screening de sífilis de acuerdo a las recomendaciones vigentes"". Page 17, Table 6 indicates screening at baseline and trimestral follow-up.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, ""Diagnóstico y tratamiento inicial de ITS"": ""En los casos en los que esté disponible, se recomienda el screening de clamidia y gonorrea (incluyendo individuos asintomáticos) a través de la realización de pruebas moleculares en muestras uretrales y/o rectales..."" Page 17, Table 6 indicates screening for gonorrhea at baseline and trimestral follow-up.",yes,"Argentina PrEP Guía de directrices clínicas_Final.pdf: Page 14, ""Diagnóstico y tratamiento inicial de ITS"": ""En los casos en los que esté disponible, se recomienda el screening de clamidia y gonorrea (incluyendo individuos asintomáticos) a través de la realización de pruebas moleculares en muestras uretrales y/o rectales..."" Page 17, Table 6 indicates screening for chlamydia at baseline and trimestral follow-up."
ARM,Armenia,no,Justification not provided,yes,"ARM PrEP Guidelines ENG.pdf: Page 3, Point 9, sub-point 3: 'clarify the status of hepatitis B if HBsAg is positive should be guided by the hepatitis B'",yes,"ARM PrEP Guidelines ENG.pdf: Page 4, continuation of Point 9, sub-point 3: 'and if HBsAg is negative, it is recommended to test and vaccinate anti-HBc'",no,Justification not provided,yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Point 9, sub-point 5: 'it's necessary to report that other sexually transmitted infections should be prevented, Before the NGO begins and receives the NGO, it is desirable to perform other sexually transmitted infections (syphilis, chlamydia) infections, Gonococcus infection, hepatitis C (HIV)) [3].'",yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Point 9, sub-point 5: 'it's necessary to report that other sexually transmitted infections should be prevented, Before the NGO begins and receives the NGO, it is desirable to perform other sexually transmitted infections (syphilis, chlamydia) infections, Gonococcus infection, hepatitis C (HIV)) [3].'",yes,"ARM PrEP Guidelines ENG.pdf: Page 4, Point 9, sub-point 5: 'it's necessary to report that other sexually transmitted infections should be prevented, Before the NGO begins and receives the NGO, it is desirable to perform other sexually transmitted infections (syphilis, chlamydia) infections, Gonococcus infection, hepatitis C (HIV)) [3].'"
AUS,Australia,yes,"PrEP-guidelines-sep-2019.pdf: Page 46, under 'Testing for STIs', states: 'Partner notification should be undertaken using the most appropriate available resources.'",yes,"PrEP-guidelines-sep-2019.pdf: Page 43, Table 7.1 lists 'Hepatitis B serology' as a required test at baseline for PrEP initiation.",yes,"PrEP-guidelines-sep-2019.pdf: Page 43, Table 7.1, in the row for 'Hepatitis B serology', includes the instruction 'Vaccinate if non-immune'.",no,PrEP-guidelines-sep-2019.pdf: The document does not mention Human Papillomavirus (HPV) or its vaccination in the context of PrEP.,yes,"PrEP-guidelines-sep-2019.pdf: Page 43, Table 7.1 recommends STI testing for 'syphilis, gonorrhoea, chlamydia' at baseline and every 90 days thereafter.",yes,"PrEP-guidelines-sep-2019.pdf: Page 43, Table 7.1 recommends STI testing for 'syphilis, gonorrhoea, chlamydia' at baseline and every 90 days thereafter.",yes,"PrEP-guidelines-sep-2019.pdf: Page 43, Table 7.1 recommends STI testing for 'syphilis, gonorrhoea, chlamydia' at baseline and every 90 days thereafter."
AUT,Austria,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 26, under 'Abstimmung des Leitlinien-Gesamttexts', states: 'Eine Partner*innen-Mitbehandlung wird empfohlen.' which translates to 'Partner co-treatment is recommended.' This is mentioned in the context of STI therapy.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Recommendation 1.6, lists 'Ausschluss einer replikativen Hepatitis-B-Infektion mittels Serologie (HBs-Antigen, anti-HBc-Antikörper)' which translates to 'Exclusion of a replicative hepatitis B infection by means of serology (HBs antigen, anti-HBc antibody)'. Additionally, the table on page 20 confirms screening for HBsAg, antiHBsAk, and antiHBcAk before starting PrEP.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Recommendation 1.6, mentions: '...bzw. Prüfung der HBV-Immunität (HBs-Antikörper, ggfs. Impfung gegen HBV)' which translates to '...or checking for HBV immunity (HBs antibodies, if necessary vaccination against HBV)'.",no,Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The document does not contain any mention of Human Papillomavirus (HPV) or its vaccine.,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Lues-Serologie' (Syphilis serology) to be performed before starting PrEP, every 3 months during PrEP, and at the end of PrEP.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Gonorrhoe-NAAT**' to be performed before starting PrEP and every 3-6 months during PrEP from pharyngeal, anorectal, and genital sites.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Chlamydien-NAAT**' to be performed before starting PrEP and every 3-6 months during PrEP from pharyngeal, anorectal, and genital sites."
BHS,The Bahamas,ERR: yes (REF: no),"HIV PrEP GuidelinesSOP Bahamas.pdf: Table 1, under the 'Rationale' for 'Counselling', lists '-To assess intimate partner violence and gender based violence'.",yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: Page 2, Section 2.2, Initiating PrEP: Baseline Evaluation and Management, lists 'Baseline Hepatitis B screening and renal function'. Table 1 also lists 'Hepatitis B surface antigen' as a recommended investigation.",yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: Table 1, under the 'Rationale' for 'Hepatitis B surface antigen' testing, states: 'If negative, consider vaccination against hepatitis B.'",no,Justification not provided,yes,"HIV PrEP GuidelinesSOP Bahamas.pdf: Table 1, under 'Investigation/Intervention', lists 'Rapid plasma reagin (RPR)' with the rationale 'To diagnose and treat syphilis infection'.",no,HIV PrEP GuidelinesSOP Bahamas.pdf: The document recommends general 'STI screening' and 'syndromic or diagnostic STI testing' but does not specifically mention Neisseria gonorrhoeae or gonorrhoea.,no,HIV PrEP GuidelinesSOP Bahamas.pdf: The document recommends general 'STI screening' and 'syndromic or diagnostic STI testing' but does not specifically mention Chlamydia trachomatis or chlamydia.
BRB,Barbados,ERR: no (REF: yes),Justification not provided,yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Hepatitis B surface antigen': The document lists testing for ""Hepatitis B surface antigen"" as an investigation at the first visit.",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Hepatitis B surface antigen', Rationale column: ""If negative, consider vaccination against hepatitis B.""",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Review vaccination history', Rationale column: ""Depending on local guidelines, epidemiology and populations, consider vaccination for human papilloma virus.""",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Screening for Sexually Transmitted Infection (STIs)', Rationale column: ""To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea).""",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Screening for Sexually Transmitted Infection (STIs)', Rationale column: ""To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea).""",yes,"Guidelines for PrEP for HIV Prevention in Barbados - Nov. 20, 2017.pdf: Page 17, Annex 3, Table, row 'Screening for Sexually Transmitted Infection (STIs)', Rationale column: ""To diagnose and treat STIs (Syphilis, Chlamydia and Gonorrhea)."""
BLR,Belarus,no,Justification not provided,yes,"BLR HIV Guidelines ENG.pdf: Page 17, paragraph 75: ""Before prescribing PrEP, the following diagnostic measures are carried out: ... determination of HBsAg.""",no,Justification not provided,no,Justification not provided,ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, paragraph 74, lists syphilis as a sexually transmitted infection (STI). Page 18, paragraph 80, states that during PrEP, 'examination for STIs' is carried out.",ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, paragraph 74, lists gonorrhea as a sexually transmitted infection (STI). Page 18, paragraph 80, states that during PrEP, 'examination for STIs' is carried out.",ERR: yes (REF: no),"BLR HIV Guidelines ENG.pdf: Page 16, paragraph 74, lists chlamydia as a sexually transmitted infection (STI). Page 18, paragraph 80, states that during PrEP, 'examination for STIs' is carried out."
BEL,Belgium,no,Justification not provided,yes,"Belgian PrEP guidelines.pdf: Page 8, in the 'Follow-up' table, under the 'Hepatitis A/B screening and immunization' row, 'AgHBs' is listed as a recommended test.",yes,"Belgian PrEP guidelines.pdf: Page 7, in the 'Follow-up' table, the row 'HBV/HAV screening and immunization' is marked under the 'Before PrEP' column.",no,Justification not provided,yes,"Belgian PrEP guidelines.pdf: Page 7, in the 'Follow-up' table, 'Syphilis screening' is marked as required 'Before PrEP' and '3months later'.",yes,"Belgian PrEP guidelines.pdf: Page 7, in the 'Follow-up' table, 'Gonoccoque and Chlamydia screening' is marked as required 'Before PrEP' and '3months later'.",yes,"Belgian PrEP guidelines.pdf: Page 7, in the 'Follow-up' table, 'Gonoccoque and Chlamydia screening' is marked as required 'Before PrEP' and '3months later'."
BEN,Benin,no,Justification not provided,yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 28, in the table under 'Required initiation steps', it lists 'To research Hepatitis of Surface Antigen' and specifies actions for both HBsAg negative and positive results, indicating screening is recommended.",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 28, in the table under 'Required initiation steps', it states for HBsAg negative results to 'Explore and offer hepatitis B vaccination (in accordance with national hepatitis guidelines)'.",no,Justification not provided,yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 31 states: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.). It is therefore recommended to make a regular monitoring (clinical and/or biological) of STIs every three months at least...'",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 31 states: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.). It is therefore recommended to make a regular monitoring (clinical and/or biological) of STIs every three months at least...'",yes,"Bening_ENG_GUIDE NATIONAL DE MISE EN ŒUVRE DE LA PROPHYLAXIE PRE EXPOSITION FINAL (1) copy.pdf: Page 31 states: 'Regularly check up on STIs: PrEP does not prevent other STIs (gonorrhea, condyloma, chlamydia, hepatitis B/C, syphilis, etc.). It is therefore recommended to make a regular monitoring (clinical and/or biological) of STIs every three months at least...'"
BIH,Bosnia and Herzegovina,no,Justification not provided,yes,"BiH HIV Guidelines ENG.pdf: Page 66, Basic laboratory testing: ""► Testing for hepatitis B because HIV PrEP drugs serve both to treat HBV, and people with active hepatitis B infection could experience a flare-up of hepatitis after the exclusion of prEP medications.""",no,Justification not provided,no,Justification not provided,yes,"BiH HIV Guidelines ENG.pdf: Page 66, Basic laboratory testing: ""► Serological testing for sexually transmitted diseases: syphilis, gonorrhea, chlamydia;""",yes,"BiH HIV Guidelines ENG.pdf: Page 66, Basic laboratory testing: ""► Serological testing for sexually transmitted diseases: syphilis, gonorrhea, chlamydia;""",yes,"BiH HIV Guidelines ENG.pdf: Page 66, Basic laboratory testing: ""► Serological testing for sexually transmitted diseases: syphilis, gonorrhea, chlamydia;"""
BWA,Botswana,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided
BRA,Brazil,ERR: yes (REF: no),"protocolo_clinico_profilaxia_prep.pdf: Page 41, Chapter 6: 'Dentre essas estratégias, está a testagem de pares e parcerias de usuários em PrEP. A proposta é que, durante as consultas de rotina nos serviços de saúde que realizam PrEP, o profissional possa ofertar ao usuário de PrEP autotestes de HIV, disponíveis nas Unidades Dispensadoras de Medicamentos (UDM), para que ele os distribua entre seus pares ou parcerias. Alternativamente, pode-se orientar o usuário de PrEP a conversar com seus pares ou parcerias sobre a importância da testagem e a sugerir que procurem algum serviço de saúde para fazer o teste, caso o usuário não deseje levar os autotestes para seus pares ou parcerias.' (Among these strategies is the testing of peers and partners of PrEP users. The proposal is that, during routine consultations at health services that provide PrEP, the professional can offer the PrEP user HIV self-tests, available at the Medication Dispensing Units (UDM), for them to distribute among their peers or partnerships. Alternatively, the PrEP user can be advised to talk to their peers or partnerships about the importance of testing and suggest they seek a health service to get tested, in case the user does not want to take the self-tests for their peers or partnerships.)",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 37, Quadro 3 (Table 3) recommends testing for Hepatitis B ('Teste para hepatite B') annually, specifying the method as 'Pesquisa de HBsAg (ex.: TR) e anti-HBs' (Search for HBsAg (e.g., rapid test) and anti-HBs).",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 20: 'A vacinação contra a hepatite B é recomendada para todas as pessoas, em qualquer faixa etária. Os segmentos populacionais com indicação de PrEP também são prioritários para receber o esquema vacinal completo (geralmente de três doses).' (Vaccination against hepatitis B is recommended for all people, at any age group. The population segments with an indication for PrEP are also priorities to receive the complete vaccination schedule (usually three doses).)",ERR: yes (REF: no),"protocolo_clinico_profilaxia_prep.pdf: Page 28, Figura 2 - Mandala da Prevenção Combinada (Figure 2 - Combined Prevention Mandala), includes a segment labeled 'Imunizar para HBV e HPV' (Immunize for HBV and HPV) as one of the combined prevention strategies discussed in the context of PrEP.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 37, Quadro 3 (Table 3) recommends a 'Teste para sífilis' (Test for syphilis) to be conducted trimestrally ('Trimestral').",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 37, Quadro 3 (Table 3) recommends 'Identificação de outras IST (clamídia e gonococo)' (Identification of other STIs (chlamydia and gonococcus)) to be conducted every six months ('Semestral') or more frequently if symptomatic.",yes,"protocolo_clinico_profilaxia_prep.pdf: Page 37, Quadro 3 (Table 3) recommends 'Identificação de outras IST (clamídia e gonococo)' (Identification of other STIs (chlamydia and gonococcus)) to be conducted every six months ('Semestral') or more frequently if symptomatic."
BFA,Burkina Faso,no,Justification not provided,yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Table 1 on page 20, under 'Bilan biologique obligatoire' (Mandatory biological assessment), lists 'AgHBs' screening at 'J0 ou inclusion' (Day 0 or inclusion).",yes,BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Table 1 on page 20 includes a row for 'Vaccination contre l'hépatite B' (Vaccination against hepatitis B) for eligible individuals (AgHBs- & AcHBs-).,no,Justification not provided,yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Table 1 on page 20, under 'Bilan biologique conseillé' (Recommended biological assessment), lists 'Syphilis (TPHA+VDRL)' screening at 'J0 ou inclusion' (Day 0 or inclusion) and then annually ('Tous les ans').",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Table 1 on page 20, under 'Bilan biologique conseillé' (Recommended biological assessment), recommends 'PCR Chlamydiase, Gonococcie' at initiation and every 6 months.",yes,"BF_Guide PrEP_Burkina Faso_vf2 (Récupération automatique).pdf: Table 1 on page 20, under 'Bilan biologique conseillé' (Recommended biological assessment), recommends 'PCR Chlamydiase, Gonococcie' at initiation and every 6 months."
BDI,Burundi,no,Justification not provided,ERR: yes (REF: no),"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, in 'APPENDIX 1: ALGORITHM OF PrEP', under 'Other recommended actions', it lists 'Hepatitis B assessment'.",ERR: yes (REF: no),"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: Page 63, in 'APPENDIX 1: ALGORITHM OF PrEP', under 'Other recommended actions', it lists 'Vaccinate if indicated' following the Hepatitis B assessment.",no,Justification not provided,no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: The document recommends a general 'Assessment and treatment of STIs if indicated' (Page 63) for PrEP users, but does not specifically mention screening for syphilis.",no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: The document recommends a general 'Assessment and treatment of STIs if indicated' (Page 63) for PrEP users, but does not specifically mention screening for Neisseria gonorrhoeae.",no,"Burundi 2020.10 PLAN DE MISE EN OEUVRE DES DIRECTIVES DE TARV 2020_VF PREFACEE_09 Oct 2020.fr.en.pdf: The document recommends a general 'Assessment and treatment of STIs if indicated' (Page 63) for PrEP users, but does not specifically mention screening for Chlamydia trachomatis."
KHM,Cambodia,no,Justification not provided,yes,"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Page 16, Section 4.2.5 states: 'Rapid screening tests for HIV 4th generation, HBsAg, HCV and syphilis will be done in the CBO DIC.' Additionally, Figure 3 on page 13 includes 'HBV' testing in the PrEP delivery diagram.",ERR: no (REF: yes),Justification not provided,no,Justification not provided,yes,"2022 - nchads-sop-prep-implementation-cambodia-2022.pdf: Page 16, Section 4.2.5 states: 'Rapid screening tests for HIV 4th generation, HBsAg, HCV and syphilis will be done in the CBO DIC.' Also, Figure 3 on page 13 indicates syphilis testing at follow-up visits (M1 and M3).",ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided
CMR,Cameroon,no,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: The document mentions ""Partner support issue"" in a table on page 15, but this is within the context of psychosocial support and does not specify STI testing, treatment, or management for the partners of PrEP users.",yes,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 12 states that at initiation, a ""Test diagnostic des hépatites"" will be performed. Page 21 further specifies this in a budget table as ""HepB testing"".",ERR: yes (REF: no),"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 12 recommends a ""Test diagnostic des hépatites puisréférence pour vaccination si négatif"" (Diagnostic test for hepatitis then referral for vaccination if negative).",no,Justification not provided,ERR: yes (REF: no),"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: Page 12 lists ""Tests biologiquesdes IST (syphilis)"" (Biological STI tests (syphilis)) to be performed at initiation. This is reinforced in a table on page 20 which lists ""Test sérologique de la syphilis et traitement"" (Serological test for syphilis and treatment).",no,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: The document recommends syndromic management for STIs (e.g., ""Évaluation syndromique des IST"" on page 15) but does not specify etiological screening for Neisseria gonorrhoeae.",no,"Cadre de MEO de la Prophylaxie Pré exposition_Final 29042019.pdf: The document recommends syndromic management for STIs (e.g., ""Évaluation syndromique des IST"" on page 15) but does not specify etiological screening for Chlamydia trachomatis."
CAN,Canada,ERR: no (REF: yes),Justification not provided,yes,"Canada_PrEP guidelines 2017.pdf: Page 6, Table 3, 'Suggested evaluation at baseline and during pre-exposure prophylaxis' recommends a 'Hepatitis B screen (surface antigen, surface antibody, core antibody)' at baseline.",yes,"Canada_PrEP guidelines 2017.pdf: Page 5, Box 4, under 'Sexually transmitted infections and viral hepatitis', states: 'vaccination for hepatitis A and B for nonimmune individuals'.",no,Justification not provided,yes,"Canada_PrEP guidelines 2017.pdf: Page 6, Table 3, 'Suggested evaluation at baseline and during pre-exposure prophylaxis' recommends 'Syphilis serology' at baseline and every 3 months.",yes,"Canada_PrEP guidelines 2017.pdf: Page 6, Table 3, 'Suggested evaluation at baseline and during pre-exposure prophylaxis' recommends 'Screening for gonorrhea and chlamydia' at baseline.",yes,"Canada_PrEP guidelines 2017.pdf: Page 6, Table 3, 'Suggested evaluation at baseline and during pre-exposure prophylaxis' recommends 'Screening for gonorrhea and chlamydia' at baseline."
CUB,Cuba,ERR: no (REF: yes),Justification not provided,yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 178, section 2.b: ""Evaluar la situación serológica del virus de la hepatitis B (VHB): La infección crónica por VHB no contraindica la administración de PrEP, pero es importante conocer la situación serológica...""",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 178, section 2.b: ""Si no hay infección crónica por VHB, las personas susceptibles deben ser vacunadas frente a esta infección.""",no,Justification not provided,yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 114, section 2.4.b: ""Realizar prueba VIH, sífilis, Ng / Ct.""",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 114, section 2.4.b: ""Realizar prueba VIH, sífilis, Ng / Ct.""",yes,"Resolucion Ministerial No. 56 del 2019.pdf: Page 114, section 2.4.b: ""Realizar prueba VIH, sífilis, Ng / Ct."""
CZE,Czech Republic,ERR: yes (REF: no),"CZE PrEP Guidelines ENG.pdf: Page 14, under 'Groups of people at increased risk', mentions: 'A suitable situation to start or restart PrEP can be: sex without a condom (planned or unexpected) diagnosis of STDs in the client or partner...'",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, under 'Initial examination', recommends 'hepatitis serology examination (HBsAg, anti-HCV, facultative anti-HAV total, anti-HBs and anti-HBc total)'.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5 states: 'Clients who have not had hepatitis B should be offered vaccination. If they have not had hepatitis B or A, it is preferable to vaccinate against both hepatitis with a combined vaccine.'",no,Justification not provided,yes,"CZE PrEP Guidelines ENG.pdf: Page 5, under 'Examination for sexually transmitted diseases', recommends 'syphilis screening serologically by a combination of one nontreponemal and one treponemal test (e.g. RRR + TPPA)'.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, under 'Examination for sexually transmitted diseases', recommends 'PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs...'.",yes,"CZE PrEP Guidelines ENG.pdf: Page 5, under 'Examination for sexually transmitted diseases', recommends 'PCR Chlamydia trachomatis and Neisseria gonorrheae in rectum, throat and urethra swabs...'."
CIV,Côte d'Ivoire,no,Justification not provided,yes,"CDI_National PrEP Guidelines.pdf: Page 9, 'Dépistage VHB' section states: '...le dépistage de l'hépatite est obligatoire avant la mise sous traitement.' The form on page 25 specifies 'Hépatite B(HBsAg)'.",yes,"CDI_National PrEP Guidelines.pdf: Page 9, 'Dépistage VHB' section states: 'La vaccination devra être faite pour les personnes AgHBs négatif.' The form on page 25 includes a checkbox 'Si négatif, série de vaccins commencé'.",no,Justification not provided,no,CDI_National PrEP Guidelines.pdf: The document mentions general STI screening ('Dépistage des IST' on page 9) but does not specifically name syphilis or Treponema pallidum as a required test.,no,CDI_National PrEP Guidelines.pdf: The document mentions general STI screening ('Dépistage des IST' on page 9) but does not specifically name Neisseria gonorrhoeae or gonorrhoea as a required test.,no,CDI_National PrEP Guidelines.pdf: The document mentions general STI screening ('Dépistage des IST' on page 9) but does not specifically name Chlamydia trachomatis or chlamydia as a required test.
KOR,Korea,no,Justification not provided,yes,"ic-49-243.pdf: Page 3, Section 4, point 3: ""Testing for hepatitis B virus (HBs Ag, HBs Ab) and hepatitis C virus (HCV Ab) should be performed before starting PrEP (AIII).""",yes,"ic-49-243.pdf: Page 3, Section 4, point 3: ""Hepatitis B virus vaccination is recommended for MSM without HBs Ab (AIII).""",no,Justification not provided,yes,"ic-49-243.pdf: Page 3, Section 5, point 7: ""Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII).""",yes,"ic-49-243.pdf: Page 3, Section 5, point 7: ""Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII).""",yes,"ic-49-243.pdf: Page 3, Section 5, point 7: ""Sexually active persons receiving PrEP should be seen at least every 6 months to conduct tests for sexually transmitted infections (i.e., syphilis, gonorrhea, chlamydia) (BII)."""
COD,Democratic Republic of the Congo,no,Justification not provided,yes,"DRC_National PrEP Guidelines.pdf: Page 34, section 2.4.4 states: 'Il est recommandé de rechercher l'hépatite B virale chez tout client à la PrEP : Si le test AgHBs est négatif...'. Page 43, Table 8, under 'Respect des périodes d'évaluation clinique et biologique,' it recommends 'Faire la sérologie pour l'Hépatite virale B au bilan initial puis annuellement'. Page 44, Table 9, shows 'Sérologie pour hépatite B' is performed at 'Initial' and '12 mois'.",yes,"DRC_National PrEP Guidelines.pdf: Page 34, section 2.4.4 states: 'Si le test AgHBs est négatif : vacciné contre le virus de l'hépatite B'.",no,Justification not provided,yes,"DRC_National PrEP Guidelines.pdf: Page 43, Table 8, under 'Respect des périodes d'évaluation clinique et biologique,' it recommends 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'. Page 44, Table 9, shows 'Sérologie de la syphilis' is performed at 'Initial' and '12 mois'.",yes,"DRC_National PrEP Guidelines.pdf: Page 43, Table 8, under 'Respect des périodes d'évaluation clinique et biologique,' it recommends 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'. Page 44, Table 9, shows 'Dépistage de la gonorrhée...' is performed at 'Initial' and '12 mois'.",yes,"DRC_National PrEP Guidelines.pdf: Page 43, Table 8, under 'Respect des périodes d'évaluation clinique et biologique,' it recommends 'Recherche des IST (gonorrhée, chlamydia, syphilis) lors du bilan initial puis à chaque visite'. Page 44, Table 9, shows 'Dépistage de la gonorrhée, de la chlamydia...' is performed at 'Initial' and '12 mois'."
DNK,Denmark,no,Justification not provided,yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, under 'Survey for:', it lists 'island Hepatitis A + B + C'. Page 5 recommends testing for 'HBs antigen' every 6 months for previously uninfected and non-vaccinated individuals.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4 states, 'In case of negative Hepatitis A and / or B serology, vaccination should be offered'.",no,Justification not provided,yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, under 'Survey for:', lists 'island Syphilis'. Page 5 recommends a 'Syphilis test' every 3 months during follow-up.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, under 'Survey for:', lists 'island Gonorrhea (urethra, pharynx and rectum)'. Page 5 recommends 'Screening for chlamydia and gonorrhea' every 3 months.",yes,"regionale_prep_anbefalinger_(2019) Denmark PrEP policy.da.en.pdf: Page 4, under 'Survey for:', lists 'island Chamydia (urethra, pharynx and rectum)'. Page 5 recommends 'Screening for chlamydia and gonorrhea' every 3 months."
ECU,Ecuador,no,Justification not provided,yes,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 144, Anexo 2. The table summarizing guidance for PrEP use states that to be eligible, a clinical assessment should be done including 'Infección documentada por Hepatitis B y estado de vacunación' (Documented Hepatitis B infection and vaccination status).",ERR: yes (REF: no),"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: Page 144, Anexo 2. The table summarizing guidance for PrEP use states that to be eligible, a clinical assessment should be done including 'Infección documentada por Hepatitis B y estado de vacunación' (Documented Hepatitis B infection and vaccination status), which implies vaccination if the user is susceptible.",no,Justification not provided,no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: The document recommends general STI testing ('testeo de... ITS') every 3 months for PrEP users on page 18, but does not specifically name syphilis as one of the STIs to screen for in this context.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: The document recommends general STI testing ('testeo de... ITS') every 3 months for PrEP users on page 18, but does not specifically name Neisseria gonorrhoeae as one of the STIs to screen for in this context.",no,"gpc_VIH_acuerdo_ministerial05-07-2019.pdf: The document recommends general STI testing ('testeo de... ITS') every 3 months for PrEP users on page 18, but does not specifically name Chlamydia trachomatis as one of the STIs to screen for in this context."
SLV,El Salvador,no,Justification not provided,yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 50, Anexo 2, Perfil de Laboratorio Clínico en la Implementación de la PrEP (cont.): The table specifies screening for Hepatitis B (VHB) using a rapid test for HBsAg at baseline/reinitiation ('Evaluación basal /reinicio') and at 6-month follow-up ('Consultas de seguimiento y reinicios: 6 meses').",ERR: yes (REF: no),"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 26, paragraph 2: During the initial consultation for PrEP, it is recommended to 'Establecer el estatus de vacunación para el Virus de Hepatitis B' (Establish the vaccination status for the Hepatitis B Virus).",no,Justification not provided,yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 50, Anexo 2, Perfil de Laboratorio Clínico en la Implementación de la PrEP (cont.): The table indicates screening for Syphilis at baseline/reinitiation ('Evaluación basal /reinicio'), at the prescription visit ('Consulta de prescripción'), and at follow-up visits at 3, 6, and 9 months ('Consultas de seguimiento y reinicios: 3, 6 y 9 meses').",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 51, Anexo 2, Perfil de Laboratorio Clínico en la Implementación de la PrEP (cont.): The laboratory profile table specifies screening for 'Neisseria g.' at baseline/reinitiation ('Evaluación basal /reinicio').",yes,"El_Salvador_lineamientostecnicosparalaprofilaxispreexposicionalvihprep-Acuerdo-2950 copy.pdf: Page 51, Anexo 2, Perfil de Laboratorio Clínico en la Implementación de la PrEP (cont.): The laboratory profile table specifies screening for 'Chlamydia t.' at baseline/reinitiation ('Evaluación basal /reinicio')."
ERI,Eritrea,no,Justification not provided,yes,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: Page 24, Table 3 'Baseline Investigations prior to PrEP initiation' lists 'Hepatitis B surface antigen (HBsAg)' with the rationale 'To identify undiagnosed hepatitis B infection'. Also, on page 29, section 2.4, it states 'every PrEP user should be tested for hepatitis B surface antigen (HBsAg)'.",no,Justification not provided,no,Justification not provided,no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document recommends 'Screening for STIs (syndromic/diagnostic)' on page 24, Table 3, and 'STI screening and treatment' on page 28, but does not specify screening for syphilis or Treponema pallidum.",no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document recommends 'Screening for STIs (syndromic/diagnostic)' on page 24, Table 3, and 'STI screening and treatment' on page 28, but does not specify screening for Neisseria gonorrhoeae.",no,"Eritrea PrEP guidelines 2019-Ministry of Health.pdf: The document recommends 'Screening for STIs (syndromic/diagnostic)' on page 24, Table 3, and 'STI screening and treatment' on page 28, but does not specify screening for Chlamydia trachomatis."
EST,Estonia,no,Justification not provided,yes,"HIV_2019rj-hiv-web Translated.pdf: Page 55, Table 6, under 'Clinically suitable' states a requirement for 'Documented hepatitis B virus infection status (HBsAg, HBsAb, HBcAb) and vaccination status'.",ERR: yes (REF: no),"HIV_2019rj-hiv-web Translated.pdf: Page 55, Table 6, under 'Clinically suitable', the requirement to check 'vaccination status' for Hepatitis B implies a recommendation to vaccinate if the person is not immune.",no,Justification not provided,no,"HIV_2019rj-hiv-web Translated.pdf: The document recommends screening for 'bacterial STIs' in general for PrEP users (Page 56, Table 6), but does not specifically name syphilis or Treponema pallidum.",no,"HIV_2019rj-hiv-web Translated.pdf: The document recommends screening for 'bacterial STIs' in general for PrEP users (Page 56, Table 6), but does not specifically name Neisseria gonorrhoeae or gonorrhoea.",no,"HIV_2019rj-hiv-web Translated.pdf: The document recommends screening for 'bacterial STIs' in general for PrEP users (Page 56, Table 6), but does not specifically name Chlamydia trachomatis or chlamydia."
SWZ,Eswatini,no,"Eswatini  PrEP Implementation guide.pdf: The document mentions discussing disclosure to a partner (Page 13) and couples testing for HIV (Page 12), but there is no mention of STI partner management, testing, or treatment for sexual partners of PrEP users diagnosed with an STI other than HIV.",yes,"Eswatini  PrEP Implementation guide.pdf: Page 12, under 'PrEP minimum package', lists 'Hepatitis screening'. Page 14, in the table under 'INITIATION STEP', specifies 'Hepatitis B surface antigen' testing. The Annex on Page 25 also includes 'Take baseline HBsAg test' in the algorithm.",yes,"Eswatini  PrEP Implementation guide.pdf: Page 14, in the table under the 'Hepatitis B surface antigen' section, the plan of action for an HBsAg negative result is to: 'Offer hepatitis B vaccination if not previously completed at 0, 1, and 6 months (as per national hepatitis guidelines)'.",no,Eswatini  PrEP Implementation guide.pdf: The document does not contain any mention of Human Papillomavirus (HPV) or HPV vaccination.,no,"Eswatini  PrEP Implementation guide.pdf: The document recommends general 'STI screening' (Page 12) and 'Syndromic screening for STIs' (Page 14), but does not specify screening for syphilis or Treponema pallidum for asymptomatic individuals.",no,"Eswatini  PrEP Implementation guide.pdf: The document recommends general 'STI screening' (Page 12) and 'Syndromic screening for STIs' (Page 14), but does not specify screening for Neisseria gonorrhoeae (NG) or gonorrhea for asymptomatic individuals.",no,"Eswatini  PrEP Implementation guide.pdf: The document recommends general 'STI screening' (Page 12) and 'Syndromic screening for STIs' (Page 14), but does not specify screening for Chlamydia trachomatis (CT) or Chlamydia for asymptomatic individuals."
ETH,Ethiopia,ERR: yes (REF: no),"PrEP Implementation manual (1).pdf: Page 14, Table – 2: Initial visit procedures: The counseling section includes 'To assess intimate partner violence and gender-based violence.'",yes,"PrEP Implementation manual (1).pdf: Page 14, Table – 2: Initial visit procedures: 'Hepatitis B surface antigen' is listed as a required investigation at the initial visit.",no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided
FJI,Fiji,no,Justification not provided,yes,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: Page 107, under the section 'Before starting PrEP, the person seeking PrEP should have the following', it lists 'Test for other STIs, and Hepatis B'. This is confirmed on page 109 under 'Baseline tests before initiating PrEP' which lists 'Test for other STI (e.g. syphilis and hepatitis)'.",no,Justification not provided,no,Justification not provided,yes,"HIV Care and Antiretroviral Therapy Guideline 3rd Edition 2022_Final Editable Version.pdf: Page 109, under 'Baseline tests before initiating PrEP', the guideline lists 'Test for other STI (e.g. syphilis and hepatitis)'.",no,Justification not provided,no,Justification not provided
FIN,Finland,ERR: no (REF: yes),"Finnish National PrEP guidelines 2019.fi.en.pdf: The document mentions sexual partners in the context of Hepatitis B vaccination (page 16), but does not mention partner notification, testing, or treatment for other STIs.",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7 recommends testing for 'S-HBsAg, S-HBcAb, S-HBsAb' before starting PrEP. Page 16 also states: 'Hepatitis A, B, and C antibodies and hepatitis B carrier (HbsAg) should be determined before initiating therapy.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, under 'HEPATITIS B STUDIES', states 'vaccination is recommended in the absence of protection'. Page 16 reinforces this: 'Hepatitis A and B vaccination is recommended if a person is not protected against these diseases.'",no,Justification not provided,yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, under 'SYPHILIS', recommends testing (S-TrpaAb) 'BEFORE GETTING STARTED' and 'EVERY 3 MONTHS'. Page 16 also states 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, under 'KLAMYDIA AND TYPPIR' (Chlamydia and Gonorrhea), recommends testing (CtGcNhO) 'BEFORE GETTING STARTED' and 'EVERY 3 MONTHS'. Page 16 confirms this: 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'",yes,"Finnish National PrEP guidelines 2019.fi.en.pdf: Page 14, Table 7, under 'KLAMYDIA AND TYPPIR' (Chlamydia and Gonorrhea), recommends testing (CtGcNhO) 'BEFORE GETTING STARTED' and 'EVERY 3 MONTHS'. Page 16 confirms this: 'Chlamydia, gonorrhea and syphilis testing should be performed before starting treatment and every three months thereafter.'"
FRA,France,no,French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 11 mentions partner notification for STIs in general but states that France lacks the framework for it. There is no specific recommendation for partner management in the context of PrEP services.,yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 27, Table 4, ""Laboratory tests to be performed before the initiation of PrEP and during follow-up"", lists ""HBV serology"" as a required test before initiation and for follow-up.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 27 states that at the first consultation for PrEP, the practitioner decides on ""the necessary vaccinations according to the screening laboratory workup."" Page 15, Box 3, which provides screening strategies for populations including those eligible for PrEP, recommends ""HBV serologies... followed by vaccination in case of negative serologies.""",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 29 recommends that ""access to the HPV vaccine should be systematically offered and available in CeGIDDs and vaccination centers to... MSM up to the age of 26 years."" CeGIDDs are mentioned as key locations for PrEP delivery.",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 27, Table 4, recommends ""STI screening"" before the initiation of PrEP and during follow-up. A footnote clarifies this includes screening for ""syphilis"".",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 27, Table 4, recommends ""STI screening"" before the initiation of PrEP and during follow-up. A footnote clarifies this includes screening for ""gonococcal infection"".",yes,"French guidelines experts-vih_prevention-depistage  2018.fr.en.pdf: Page 27, Table 4, recommends ""STI screening"" before the initiation of PrEP and during follow-up. A footnote clarifies this includes screening for ""chlamydia""."
GEO,Georgia,no,Justification not provided,yes,"GEO PEP and PrEP Guidelines.pdf: Page 16, under the 'Every six months' section, lists 'HBV serology (HBsAg, anti-HBc, anti-HBs)'. Table 5 on page 17 also lists 'HBV serology (HBsAg, anti-HBc, anti-HBs)' at the initial phase.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11 states: 'HBV serological status must be determined before PrEP initiation. If the result is negative, the test should be repeated every 6 months. If HBV seromarkers are not detected, beneficiary should be offered hepatitis B vaccination;'",no,Justification not provided,yes,"GEO PEP and PrEP Guidelines.pdf: Page 11 states 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes a serologic test for syphilis...'. Page 16, under the 'Every six months' section, lists 'Serological test for syphilis'.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11 states 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes... nucleic acid-based molecular tests for gonorrhea and chlamydia.' Page 16, under the 'Every six months' section, lists 'Nucleic acid-based molecular testing on urine samples to detect gonorrhea and chlamydia'.",yes,"GEO PEP and PrEP Guidelines.pdf: Page 11 states 'Screening for sexually transmitted infections is necessary before and during PrEP. This includes... nucleic acid-based molecular tests for gonorrhea and chlamydia.' Page 16, under the 'Every six months' section, lists 'Nucleic acid-based molecular testing on urine samples to detect gonorrhea and chlamydia'."
DEU,Germany,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 26, under 'Abstimmung des Leitlinien-Gesamttexts', states: 'Eine Partner*innen-Mitbehandlung wird empfohlen.' which translates to 'Partner co-treatment is recommended.' This is mentioned in the context of STI therapy.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Recommendation 1.6, lists 'Ausschluss einer replikativen Hepatitis-B-Infektion mittels Serologie (HBs-Antigen, anti-HBc-Antikörper)' which translates to 'Exclusion of a replicative hepatitis B infection by means of serology (HBs antigen, anti-HBc antibody)'. Additionally, the table on page 20 confirms screening for HBsAg, antiHBsAk, and antiHBcAk before starting PrEP.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: Page 15, Recommendation 1.6, mentions: '...bzw. Prüfung der HBV-Immunität (HBs-Antikörper, ggfs. Impfung gegen HBV)' which translates to '...or checking for HBV immunity (HBs antibodies, if necessary vaccination against HBV)'.",no,Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The document does not contain any mention of Human Papillomavirus (HPV) or its vaccine.,yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Lues-Serologie' (Syphilis serology) to be performed before starting PrEP, every 3 months during PrEP, and at the end of PrEP.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Gonorrhoe-NAAT**' to be performed before starting PrEP and every 3-6 months during PrEP from pharyngeal, anorectal, and genital sites.",yes,"Austria -Germany Leitlinien zur PrEP_Stand 2018.pdf: The table on page 20, under '2.1 Notwendige Begleit- und Laboruntersuchungen', lists 'Chlamydien-NAAT**' to be performed before starting PrEP and every 3-6 months during PrEP from pharyngeal, anorectal, and genital sites."
GHA,Ghana,no,Justification not provided,yes,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: Page 149, under 'Summary of Pre-exposure prophylaxis visits and procedures', it states: ""Conduct relevant laboratory tests—HIV test, Creatinine Clearance and HBsAg and Confirm eligibility"" for initiation. For follow-up, it states: ""3 monthly afterwards—HIV test, Pregnancy test, HBsAg (at 6 months only).""",no,Justification not provided,no,Justification not provided,yes,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: Page 150, under follow-up procedures, it states: ""6 monthly afterwards—CrCl, STI symptom screening, rapid syphilis test and HIV test.""",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: The document mentions ""Provide STI treatment if indicated"" and ""STI symptom screening"" (Page 149-150), but does not specifically name Neisseria gonorrhoeae or gonorrhea for screening.",no,"Finale_CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA _booklet copy NEW FINAL (2).pdf: The document mentions ""Provide STI treatment if indicated"" and ""STI symptom screening"" (Page 149-150), but does not specifically name Chlamydia trachomatis or Chlamydia for screening."
GUY,Guyana,ERR: yes (REF: no),"PrEP Guyana Guidelines Final.pdf: Page 52, Item 5: 'discussing HIV and STI status and/or testing with partner'. Page 57, 'Additional Notes': 'Counsel on ... intimate partner violence'.",yes,"PrEP Guyana Guidelines Final.pdf: Page 22, Table 1: Recommends testing for 'HBV (Hepatitis B surface antigen (HBsAg))' before starting PrEP.",yes,"PrEP Guyana Guidelines Final.pdf: Page 22, Table 1: For HBV (Hepatitis B surface antigen (HBsAg)), it states 'If HBsAg is not detected, consider vaccination'.",ERR: yes (REF: no),"PrEP Guyana Guidelines Final.pdf: Page 59, Annex 6: 'Depending on local guidelines, epidemiology and populations, consider vaccination for human papilloma virus.'",yes,"PrEP Guyana Guidelines Final.pdf: Page 22, Table 1: Recommends screening for 'Syphilis (treponemal antibodies)' and 'Syphilis (rapid plasma reagintiter)' before starting PrEP, with follow-up testing every three to six months.",yes,"PrEP Guyana Guidelines Final.pdf: Page 22, Table 1: Recommends screening for 'Neisseria gonorrhoeae (GC)' before starting PrEP, with follow-up testing every three to six months.",yes,"PrEP Guyana Guidelines Final.pdf: Page 22, Table 1: Recommends screening for 'Chlamydia trachomatis (CT)' before starting PrEP, with follow-up testing every three to six months."
HTI,Haiti,no,Justification not provided,yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 10, Section 4. Bilan Initial: 'Antigène HBs si disponible (antigène de surface de l'hépatite B)'.",ERR: yes (REF: no),"PrEP_ Haiti Guidelines Final_.pdf: Page 19, ANNEXE 4, Section F: 'Si le résultat est négatif, quelles sont les dates de vaccination VHB qui ont été fournies'. This implies that vaccination is recommended for HBV-negative individuals.",no,Justification not provided,yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 10, Section 4. Bilan Initial: 'Tests de dépistage rapide du VIH et de la syphilis'.",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 11, Section 6. Suivi du Client Placé Sous PrEP: 'Effectuer des tests d'IST recommandés pour toute personne sexuellement active (syphilis, gonorrhée, chlamydia).'",yes,"PrEP_ Haiti Guidelines Final_.pdf: Page 11, Section 6. Suivi du Client Placé Sous PrEP: 'Effectuer des tests d'IST recommandés pour toute personne sexuellement active (syphilis, gonorrhée, chlamydia).'"
HND,Honduras,ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 36, item 5: The guidance recommends to '[e]xplore partner violence and refer to services when appropriate' ('Explorar violencia de pareja y referir a los servicios cuando proceda.').",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 22, section 7.7.1.2.6 recommends testing for Hepatitis B surface antigen (HBsAg) as an additional laboratory test ('Pruebas diagnósticas de detección de ITS: Antígeno de superficie del virus de Hepatitis B (HBsAg)').",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 22, section 7.7.1.2.6: 'If the results are negative for HBV, consider vaccination against HBV' ('Si los resultados son negativos para el VHB, considerar la vacunación contra el VHB.'). This is also mentioned on page 13 and page 22 (section 7.7.1.3.2).",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 22, section 7.7.1.3.2: '...consider vaccination against hepatitis A and HBV, the human papillomavirus (HPV) according to current national regulations' ('...considerar la vacunación contra la hepatitis A y VHB, el virus del papiloma humano (VPH) según normativa nacional vigente').",yes,"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 22, section 7.7.1.2.6 recommends testing for syphilis ('Prueba para diagnosticar y tratar la sífilis según normativa.'). The form in Annex 7 also specifies a diagnostic test for Syphilis (Page 47).",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 47, Annex 7: The 'Form for pre-exposure prophylaxis (PrEP) for HIV infection' includes 'Gonorrea' (Gonorrhea) as a specific diagnostic test to be performed under the section for Sexually Transmitted Infections (ITS).",ERR: yes (REF: no),"Honduras_LINEAMIENTOS PARA PROVEER LA PrEP RESOLUCION 2022 FINAL copy.pdf: Page 47, Annex 7: The 'Form for pre-exposure prophylaxis (PrEP) for HIV infection' includes 'Clamidia' (Chlamydia) as a specific diagnostic test to be performed under the section for Sexually Transmitted Infections (ITS)."
ISL,Iceland,no,Justification not provided,yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, under 'First come', lists 'Antibody testing against HIV, syphilis and hepatitis B and C'. Page 3, Figure 2, also shows blood tests for HBV at weeks 11, 23, 35, and 47.",no,Justification not provided,no,Justification not provided,yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 1, under 'First come', lists 'Antibody testing against HIV, syphilis and hepatitis B and C'. Page 3, Figure 2, also shows blood tests for syphilis at weeks 11, 23, 35, and 47.",yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 3, Figure 2, shows screening for 'Chlamydia and gonorrhea' at weeks 12, 24, 36, and 48. Page 3 also mentions monitoring for 'symptoms of acute HIV infection, chlamydia and gonorrhea'.",yes,"Iceland_PrEP_guidelines_2018.is.en.pdf: Page 3, Figure 2, shows screening for 'Chlamydia and gonorrhea' at weeks 12, 24, 36, and 48. Page 3 also mentions monitoring for 'symptoms of acute HIV infection, chlamydia and gonorrhea'."
IND,India,yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 34, in the table for STI management, under syndromes like 'Urethral discharge' and 'Cervical discharge syndrome', it lists 'Partner/s treatment' as part of the management plan.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, the table 'Baseline investigations' lists 'HBsAg' as a required investigation with the rationale 'To assess Hepatitis B, specifically in MSM, TG/TS and IDU population'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, in the 'Baseline investigations' table, under the rationale for HBsAg screening, it states: 'If negative, consider vaccination against hepatitis B'. Also, page 48 states 'Hepatitis B vaccination is recommended for people at substantial risk of HBV or HIV infection.'",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 39, in the summary table under the 'Vaccination' section, it recommends 'Human papillomavirus vaccine (and expand on this)'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, the 'Baseline investigations' table lists 'VDRL/RPR' with the rationale 'To rule out syphilis'. It also explicitly states 'Screen for syphilis -RPR/VDRL Test' under STI screening.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, in the 'Baseline investigations' table under STI screening for settings with diagnostic facilities, it states: 'For MSM and TG/TS, NAAT testing is recommended for chlamydia and gonorrhoea... (M-PCR for Tp, Hd. HSV, Tv, Ng,Ct).' and 'For females, NAAT testing is recommended for gonorrhoea... (M-PCR for Tp, Hd. HSV, Tv, Ng,Ct)...'.",yes,"India_NACO PrEP technical guidelines - May 2022 copy.pdf: Page 36, in the 'Baseline investigations' table under STI screening for settings with diagnostic facilities, it states: 'For MSM and TG/TS, NAAT testing is recommended for chlamydia and gonorrhoea... (M-PCR for Tp, Hd. HSV, Tv, Ng,Ct).'"
IDN,Indonesia,no,Justification not provided,yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 31, Table 3.6 lists 'Hepatitis B (HBsAg)' as a prerequisite for PrEP for potential MSM users choosing a PrEP-ED regimen.",yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 76, Appendix 6, in the follow-up column for a non-reactive HBsAg test, states: 'If HBsAg is nonreactive but at risk for Hep B, recommend Hep B vaccine.'",no,Justification not provided,yes,"Indonesia_Juknis PrEP_ENG.pdf: Page 31 states, 'STI screening can be done based on a syndromic approach and simple laboratory tests, including syphilis, which are available at health facilities.' Page 76, Appendix 6, also lists STI examination '(including syphilis)'.",ERR: no (REF: yes),Indonesia_Juknis PrEP_ENG.pdf: The document mentions gonorrhea as an STI not prevented by PrEP (Page 23) but does not specifically recommend screening for it. The guidance refers to a general 'syndromic approach' for STIs.,ERR: no (REF: yes),Indonesia_Juknis PrEP_ENG.pdf: The document mentions chlamydia as an STI not prevented by PrEP (Page 23) but does not specifically recommend screening for it. The guidance refers to a general 'syndromic approach' for STIs.
IRN,Iran,no,Justification not provided,yes,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: Page 28, in the section on considerations before starting PrEP, states: 'Hepatitis C infection B Or hepatitis vaccination B Be specific. He is suffering from hepatitis B, Decision in relation to start PrEP The individual should be diagnosed with hepatitis B after examination.'",yes,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: Page 27 states 'Provider prEP There is an opportunity to increase access to other health services such as social support, hepatitis vaccination B...'. Additionally, page 28 mentions 'Hepatitis C infection B Or hepatitis vaccination B Be specific.' as a consideration before starting PrEP.",no,"Iran_PEP_PreP Guideline_2017.ps.en.pdf: While HPV vaccination is mentioned on page 26, it is discussed in a general sexual health context before the specific PrEP section begins and is not explicitly linked to PrEP services or users.",ERR: no (REF: yes),Justification not provided,no,Justification not provided,no,Justification not provided
IRL,Ireland,yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 4, under the list of services for individuals on PrEP, includes 'Partner notification'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 8, section 4.2.1 'First visit', under recommended assessment, lists 'HBV testing, directed by history'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 8, section 4.2.1 'First visit', under recommended assessment, lists 'Start HBV vaccination if immunity unknown'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 7, section 4.1 'History & discussion to document', under vaccination needs, lists 'Hepatitis A, B (all) and HPV (<26 years)'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 8, section 4.2.1 'First visit', under recommended assessment, lists 'Syphilis serology'. Page 9, section 4.2.2 'Subsequent visits' also lists 'Syphilis serology'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 8, section 4.2.1 'First visit', under recommended assessment, lists 'Chlamydia and Gonorrhea NAAT testing'. Page 9, section 4.2.2 'Subsequent visits' also lists 'Chlamydia and Gonorrhea NAAT testing'.",yes,"Ireland practical-prep-guidance-december-2017.pdf: Page 8, section 4.2.1 'First visit', under recommended assessment, lists 'Chlamydia and Gonorrhea NAAT testing'. Page 9, section 4.2.2 'Subsequent visits' also lists 'Chlamydia and Gonorrhea NAAT testing'."
ISR,Israel,no,"Israel PrEP guidance.PDF: The document recommends follow-up of the HIV status of partners (Page 4), but there is no mention of testing or treating partners for other STIs.",yes,Israel PrEP guidance.PDF: The table on Page 8 recommends testing for 'HBsAg (Hepatitis B surface Antigen)' before starting treatment.,yes,"Israel PrEP guidance.PDF: Page 6 states: 'For patients negative for HBV, vaccination should be offered before starting treatment'. The table on Page 8 also recommends referring unvaccinated patients for vaccination.",no,Justification not provided,yes,"Israel PrEP guidance.PDF: The table on Page 8, under 'בדיקות מחלות מין' (STI tests), lists 'עגבת' (syphilis) to be tested before starting treatment and every six months.",yes,"Israel PrEP guidance.PDF: The table on Page 8, under 'בדיקות מחלות מין' (STI tests), lists 'זיבה' (gonorrhea) to be tested before starting treatment and every six months.",yes,"Israel PrEP guidance.PDF: The table on Page 8, under 'בדיקות מחלות מין' (STI tests), lists 'כלמידה' (chlamydia) to be tested before starting treatment and every six months."
ITA,Italy,no,Justification not provided,yes,"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 4, paragraph 'While taking Truvada to treat HIV or to reduce the risk of getting HIV:', states: 'Find out if you are infected with the hepatitis B virus (HBV) before you start taking Truvada.'",ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: yes (REF: no),"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 3, under 'Warnings and Precautions', states: 'Get tested for other sexually transmitted infections such as syphilis and gonorrhea. These infections facilitate HIV infection.'",ERR: yes (REF: no),"Italy_Truvada Regulatory Approval_2019.it.en.pdf: Page 3, under 'Warnings and Precautions', states: 'Get tested for other sexually transmitted infections such as syphilis and gonorrhea. These infections facilitate HIV infection.'",no,Justification not provided
KAZ,Kazakhstan,no,Justification not provided,ERR: yes (REF: no),"KAZ HIV Guidelines ENG.pdf: Page 30, paragraph 10: 'It is recommended to test for STIs (including VH) at the beginning of PrEP and regularly during the use of PrEP, with the informed consent of the client.'",no,Justification not provided,no,Justification not provided,yes,"KAZ HIV Guidelines ENG.pdf: Page 33, Section 'At least once every 6 months, for:', bullet point 5: 'STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).'",yes,"KAZ HIV Guidelines ENG.pdf: Page 33, Section 'At least once every 6 months, for:', bullet point 5: 'STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).'",yes,"KAZ HIV Guidelines ENG.pdf: Page 33, Section 'At least once every 6 months, for:', bullet point 5: 'STI screening behaviors for sexually active adolescents and adults (e.g., syphilis, gonorrhea, and chlamydia for both men and women, even if they are asymptomatic).'"
KEN,Kenya,no,Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,no,Justification not provided,ERR: no (REF: yes),"Kenya-PrEP-Framework.pdf: The document mentions general 'STI screening' (e.g., Page 46) but does not specify screening for syphilis or Treponema pallidum.",no,"Kenya-PrEP-Framework.pdf: The document mentions general 'STI screening' (e.g., Page 46) but does not specify screening for Neisseria gonorrhoeae or gonorrhoea.",no,"Kenya-PrEP-Framework.pdf: The document mentions general 'STI screening' (e.g., Page 46) but does not specify screening for Chlamydia trachomatis or Chlamydia."
KGZ,Kyrgyz Republic,no,Justification not provided,yes,"KGZ HIV Guidelines ENG.pdf: Page 12, Table 'Clinical monitoring for PrEP', Row 'Test for HBV infection.'",yes,"KGZ HIV Guidelines ENG.pdf: Page 12, Table 'Clinical monitoring for PrEP', Row 'Test for HBV infection.', Note column: 'Redirect the client to receiveHBV vaccination.'",no,Justification not provided,yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', Row 'Testing for STIs', Note column: 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'",yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', Row 'Testing for STIs', Note column: 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'",yes,"KGZ HIV Guidelines ENG.pdf: Page 11, Table 'Clinical monitoring for PrEP', Row 'Testing for STIs', Note column: 'Testing for STIs (syphilis, chlamydia, trichomoniasis, gonorrhea) for sexually active people is carried out in accordance with current recommendations.'"
LAO,Lao People's Democratic Republic,no,Justification not provided,yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Page 27, Table 2. Clinical and laboratory monitoring requirements: Lists 'HBV serology' as 'YES' for baseline monitoring. Footnote 26 clarifies 'Hepatitis B serology is indicated... HBsAg negative... HBsAg positive...'",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Page 27, footnote 26: 'HBsAg negative: offer hepatitis B vaccination (as per national hepatitis guidelines).'",no,Justification not provided,yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Page 27, Table 2, footnote 23: 'STI screening (syphilis, N gonorrhea and C trachomatis) should be offered through syndromic approach or using a laboratory diagnostic test'.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Page 27, Table 2, footnote 23: 'STI screening (syphilis, N gonorrhea and C trachomatis) should be offered through syndromic approach or using a laboratory diagnostic test'.",yes,"Lao PDR PrEP Guidelines_Print_EN version 2021.pdf: Page 27, Table 2, footnote 23: 'STI screening (syphilis, N gonorrhea and C trachomatis) should be offered through syndromic approach or using a laboratory diagnostic test'."
LSO,Lesotho,no,Justification not provided,yes,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 36, Table 3.1 'Baseline Laboratory Tests for Clients Initiating PrEP' lists 'Hepatitis B surface antigen (HBsAg)' as a recommended test at initiation.",ERR: yes (REF: no),"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 36, Table 3.1 'Baseline Laboratory Tests for Clients Initiating PrEP', the rationale for HBsAg screening includes 'To identify those eligible for vaccination against Hepatitis B'.",ERR: no (REF: yes),Justification not provided,yes,"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 39, under 'Other baseline laboratory tests', it states 'An RPR, Hepatitis B screen and pregnancy test must be performed on all new PrEP clients in the first three months of starting PrEP'. Table 3.3 on the same page also lists 'RPR/VDRL' under Laboratory Evaluation for the first visit.",ERR: yes (REF: no),"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 36, Table 3.1 recommends 'STI diagnostic tests' at baseline, and Page 41 states, 'Clients will benefit from screening for STIs at every visit.' Gonorrhoea is mentioned on page 35 as an example of an STI that increases risk.",ERR: yes (REF: no),"Final Interactive -Lesotho HIV Prevention-Treatment and Care guideline (2022).pdf: Page 36, Table 3.1 recommends 'STI diagnostic tests' at baseline, and Page 41 states, 'Clients will benefit from screening for STIs at every visit.' Chlamydia is mentioned on page 35 as an example of an STI that increases risk."
MYS,Malaysia,no,Justification not provided,yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Initial Laboratory Testing: ""3. Serology for Hepatitis A, B and C viruses (Hep A IgG, Hep B sAg, Hep B sAb and Hep B core Ab, Hep C Ab)"".",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 86, Section 17.4, Initial Laboratory Testing: ""Hepatitis B vaccination should be provided to susceptible patients who are Hep B sAg and sAb neg"".",no,Justification not provided,yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 87, Section 17.5, Post-PrEP Follow-Up: ""Rapid plasma reagin test for syphilis"" is listed under STI Screen.",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 87, Section 17.5, Post-PrEP Follow-Up: ""NAAT for gonococcal (GC) and chlamydial (CT) infections3-site screening based on exposure (genital, rectal, pharyngeal)"" is listed under STI Screen.",yes,"Malaysian-Consensus-Guidelines-on-Antiretroviral-Therapy-2017-MINISTRY-OF-HEALTH-MALAYSIA.pdf: Page 87, Section 17.5, Post-PrEP Follow-Up: ""NAAT for gonococcal (GC) and chlamydial (CT) infections3-site screening based on exposure (genital, rectal, pharyngeal)"" is listed under STI Screen."
MLI,Mali,no,Justification not provided,yes,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: Page 81, ""Consultation initiale: Jour 0"": ""Bilan VIH, IST et Hépatite B. S'enquérir d'autres médications en cours""",no,Justification not provided,no,Justification not provided,no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: The document recommends STI screening ('Bilan VIH, IST et Hépatite B' on page 81) but does not specify which pathogens to screen for, such as syphilis.",no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: The document recommends STI screening ('Bilan VIH, IST et Hépatite B' on page 81) but does not specify which pathogens to screen for, such as Neisseria gonorrhoeae.",no,"Mali_NORMES-ET-PROTOCOLES-DE-PRISE-EN-CHARGE-ANTIRETROVIRALE_VALIDE_19-VF-070220-1.pdf: The document recommends STI screening ('Bilan VIH, IST et Hépatite B' on page 81) but does not specify which pathogens to screen for, such as Chlamydia trachomatis."
MEX,Mexico,no,"Mexico Gu_aARV_2019_09Noviembre.pdf: The document mentions evaluating 'violencia de pareja' (partner violence) on page 87 in the counseling section for PrEP, but it does not mention partner testing or treatment for STIs.",yes,Mexico Gu_aARV_2019_09Noviembre.pdf: Page 86 recommends: 'Se recomienda realizar una prueba de antígeno de superficie de la hepatitis B (HBsAg) antes de iniciar PrEP.' (It is recommended to perform a test for hepatitis B surface antigen (HBsAg) before starting PrEP). This is also listed in Table II-C on page 87.,yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 87, in Table II-C, for the intervention 'Antígeno Hep B' (Hep B Antigen), the observation is 'Negativo: considerar vacuna' (Negative: consider vaccine).",yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 87, in Table II-C, under the intervention 'Historial de vacunación' (Vaccination history), it lists 'Hepatitis A, VPH, tétanos y meningitis', indicating that HPV vaccination status should be checked as part of the initial PrEP consultation.",yes,"Mexico Gu_aARV_2019_09Noviembre.pdf: Page 87, Table II-C lists 'VDRL' as an intervention at the first PrEP consultation, with the observation 'Diagnóstico y tratamiento de sífilis' (Diagnosis and treatment of syphilis).",no,Justification not provided,no,Justification not provided
MDA,Moldova,ERR: yes (REF: no),"Moldova PrEP clinical protocol 2018.pdf: Page 14, in the table for initial PrEP visit, under 'Consiliere' (Counseling), it recommends to 'evaluat violența partenerului intim precum și violența bazată pe factorul gender' (assess intimate partner violence and gender-based violence). Page 18 also mentions assessing 'violența din partea partenerului intim' (violence from the intimate partner).",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 14, Table 1, 'INVESTIGAȚII PROPUSE LA DEBUTAREA PrEP (prima vizită)' (PROPOSED INVESTIGATIONS AT PrEP INITIATION (first visit)) lists screening for 'HBsAg'. Page 23, under 'Teste iniţiale' (Initial tests), recommends 'HBsAg – o dată pe an' (HBsAg – once a year).",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 14, Table 1, in the row for HBsAg, it states 'Dacă e negativ, de recomandat vaccinarea anti-HVB' (If negative, vaccination against HVB is recommended). Also, in the row 'Anamneza vaccinelor suportate' (History of supported vaccines), it states 'de luat în considerare vaccinarea pentru HVB (HVA)' (consider vaccination for HVB).",ERR: yes (REF: no),"Moldova PrEP clinical protocol 2018.pdf: Page 14, Table 1, in the row 'Anamneza vaccinelor suportate' (History of supported vaccines), it states 'de luat în considerare vaccinarea pentru HVB (HVA), papilloma virus uman' (consider vaccination for HVB (HVA), human papilloma virus).",yes,"Moldova PrEP clinical protocol 2018.pdf: Page 14, Table 1, 'INVESTIGAȚII PROPUSE LA DEBUTAREA PrEP (prima vizită)' (PROPOSED INVESTIGATIONS AT PrEP INITIATION (first visit)) lists 'Teste de diagnostic al sifilisului' (Tests for the diagnosis of syphilis). Page 23, under 'Teste iniţiale' (Initial tests), recommends 'Screening ITS (Syphilis) – fiecare 6 luni' (STI Screening (Syphilis) – every 6 months).",no,"Moldova PrEP clinical protocol 2018.pdf: The document mentions 'gonoreea' (gonorrhea) on page 18 as an STI that PrEP does not protect against, but it is not specifically mentioned in the recommended screening schedules on pages 14 or 23, which only specify syphilis.",no,"Moldova PrEP clinical protocol 2018.pdf: The document mentions 'chlamydia' on page 18 as an STI that PrEP does not protect against, but it is not specifically mentioned in the recommended screening schedules on pages 14 or 23, which only specify syphilis."
MNG,Mongolia,no,Justification not provided,yes,"305 ENG.pdf: Page 136, Control section: 'Conduct HBV screening tests, vaccinate regardless of the decision on PrEP and provide treatment if it’s active infection'.",yes,"305 ENG.pdf: Page 136, Control section: 'Conduct HBV screening tests, vaccinate regardless of the decision on PrEP and provide treatment if it’s active infection'.",no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided
MMR,Myanmar,no,Justification not provided,yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, Table 3: A baseline test for HBsAg is recommended. Page 21, Section 4: ""All persons screened for PrEP should be tested for hepatitis B surface antigen (HBsAg) once, at or within one to three months of PrEP initiation.""",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, Table 3: Under 'Remark' for HBsAg, it states ""If negative, consider vaccination against HBV."" Page 21, Section 4: ""Consider vaccination if HBsAg is not detected and there is no documented history of a completed vaccine series for Hepatitis B Virus (HBV).""",no,Justification not provided,yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, Table 3: Recommends testing for ""STI (Syphilis, GC, CT)"" at baseline and every 6 months.",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, Table 3: Recommends testing for ""STI (Syphilis, GC, CT)"" at baseline and every 6 months, where GC stands for gonococcus.",yes,"2023Aug_PrEP_SOP_Final_print.pdf: Page 19, Table 3: Recommends testing for ""STI (Syphilis, GC, CT)"" at baseline and every 6 months, where CT stands for Chlamydia trachomatis."
MKD,North Macedonia,no,Justification not provided,yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates an HBsAg test is performed at initiation (""-1. or 0. Sunday"").",yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates HBV vaccination is performed at initiation (""-1. or 0. Sunday"").",ERR: yes (REF: no),"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates HPV vaccination is performed at initiation (""-1. or 0. Sunday"").",yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates ""Syphilis serologically"" testing at initiation, 6 months, and 12 months.",yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates ""N. gonorrhea PCR"" testing at initiation, 6 months, and 12 months.",yes,"MKD PrEP Guidelines ENG.pdf: Page 17, Table 2, ""Successive tests and procedures during the PrEP pilot project"", indicates ""H. trachomatis PCR"" testing at initiation, 6 months, and 12 months."
NAM,Namibia,no,Justification not provided,yes,"Namibia_national_guidelines_art.pdf: Page 99, Table 5.1: In the 'Screening and PrEP initiation' section, under 'Recommended Procedures', it lists 'Tests—HIV test, CrCl, HBsAg'. It is also listed for follow-up: 'HBsAg (at 6 months only)'.",no,Justification not provided,no,Justification not provided,yes,"Namibia_national_guidelines_art.pdf: Page 99, Table 5.1: In the 'Four-month follow-up and 3-monthly maintenance visits' section, under 'Tests', it specifies '6 monthly afterwards—CrCl, STI symptom screening, rapid syphilis test and HIV test'.",no,Justification not provided,no,Justification not provided
NPL,Nepal,no,Justification not provided,yes,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 17, in the table under 'Service packages including investigations', 'Hepatitis B screening' is recommended at baseline. Page 18, Table 3, states, 'Hepatis B antigen screening is recommended at the initiation of PrEP.'",ERR: no (REF: yes),Justification not provided,no,Justification not provided,yes,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: Page 16, Table 2 recommends 'syphilis screening' at baseline and at all follow-up visits. Page 18, Table 3, specifies 'Syphilis screening with Rapid Plasma Reagin (RPR) should be part of symptom screening, especially among KPs.'",no,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: The document recommends 'STI syndromic screen-ing' (Page 16) and mentions gonorrhea as an STI not prevented by PrEP (Page 25), but does not recommend specific pathogen-based screening for Neisseria gonorrhoeae.",no,"National SOP HIV  PrEP-Nepal -Final _2022-NCASC Nepal.pdf: The document recommends 'STI syndromic screen-ing' (Page 16) and mentions chlamydia as an STI not prevented by PrEP (Page 25), but does not recommend specific pathogen-based screening for Chlamydia trachomatis."
NLD,Netherlands,ERR: yes (REF: no),"Netherlands_PrEP_dossier_2017.pdf: Page 41, Table 4.2: Under the 'Public Health Care' section for PrEP services, it lists 'partnerwaarschuwing' (partner notification) as an area of expertise for the Sexual Health Centers (CSG).",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 40, Table 4.1: 'HBV status en vaccinatie' (HBV status and vaccination) is listed as a required medical control 'voor start PrEP' (before starting PrEP).",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 40, Table 4.1: 'HBV status en vaccinatie' (HBV status and vaccination) is listed as a required medical control 'voor start PrEP' (before starting PrEP). Footnote 5 clarifies: 'Screen volgens landelijk beleid en vaccineer indien geindiceerd' (Screen according to national policy and vaccinate if indicated).",ERR: no (REF: yes),Justification not provided,yes,"Netherlands_PrEP_dossier_2017.pdf: Page 40, Table 4.1: 'Soa testen' (STI tests) are required before starting PrEP and every 3 months after starting. This explicitly includes 'syfilis serologie' (syphilis serology).",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 40, Table 4.1: 'Soa testen' (STI tests) are required before starting PrEP and every 3 months after starting. This explicitly includes testing for 'Gonnoroe NAAT' (Gonorrhoea NAAT).",yes,"Netherlands_PrEP_dossier_2017.pdf: Page 40, Table 4.1: 'Soa testen' (STI tests) are required before starting PrEP and every 3 months after starting. This explicitly includes testing for 'Chlamydia'."
NZL,New Zealand,yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 47, under the heading 'Testing for STIs', states: 'Partner notification should be undertaken using the most appropriate available resources.'",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 23 lists 'Hepatitis B (if not immune)' as a required investigation for the initial Special Authority application. Page 27 further specifies that 'Hepatitis A, HBV and HCV infection status should be documented by screening serology when PrEP is initiated.' Table 7.1 on page 44 also includes 'Hepatitis B serology' at baseline and follow-up.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 27, under 'Assessment of hepatitis A, B and C status', states: 'Vaccination against hepatitis A and HBV is recommended for all susceptible priority populations...'. Table 7.1 on page 44 also notes 'Vaccinate if non-immune' under the entry for Hepatitis B serology.",no,ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: The document does not contain any mention of Human Papillomavirus or HPV vaccination.,yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 23 lists 'Syphilis' as a required investigation. Page 27 recommends clinicians 'screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Table 7.1 on page 44 lists screening for 'STI (i.e. syphilis, gonorrhoea, chlamydia)' at baseline and every 3 months.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 27 recommends clinicians 'screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Table 7.1 on page 44 lists screening for 'STI (i.e. syphilis, gonorrhoea, chlamydia)' at baseline and every 3 months. Box 7.1 on page 45 specifies testing for 'Neisseria gonorrhoea'.",yes,"ASHM_PrEP_NZ_guidelines_FINAL_Sept2021.pdf: Page 27 recommends clinicians 'screen for STIs (specifically gonorrhoea, chlamydia and infectious syphilis)'. Table 7.1 on page 44 lists screening for 'STI (i.e. syphilis, gonorrhoea, chlamydia)' at baseline and every 3 months. Box 7.1 on page 45 specifies 'urine PCR tests for chlamydia'."
NGA,Nigeria,no,Justification not provided,yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 157, paragraph 2, bullet 1: ""Persons eligible for PrEP should be screened for Hepatitis B. People with detectable HBsAg...""",no,Justification not provided,no,Justification not provided,yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, paragraph 2, bullet 1: ""Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)""",yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, paragraph 2, bullet 1: ""Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)""",yes,"Nigeria_National Guidelines for HIV Prevention Treatment and Care (2016).pdf: Page 159, paragraph 2, bullet 1: ""Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia)"""
NOR,Norway,no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided,ERR: yes (REF: no),"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: Page 10, paragraph 1: 'Frequent testing for other soi, such as gonorrhea and syphilis, is recommended as an important offer to PrEP users.'",ERR: yes (REF: no),"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: Page 10, paragraph 1: 'Frequent testing for other soi, such as gonorrhea and syphilis, is recommended as an important offer to PrEP users.'",no,"15-774-10 PrEP kunnskapsgrunnlag og anbefaling 120816.no.en.pdf: The document mentions chlamydia when reporting the results of a clinical study (Page 13, paragraph 3) but does not explicitly recommend screening for it as part of the guidance."
PAK,Pakistan,ERR: no (REF: yes),Justification not provided,yes,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 4, under section '1.2: Monitoring prior to and while on PrEP', states, 'Therefore, hepatitis-B status, with hepatitis B surface antigen testing should be documented prior to PrEP.' Page 5, Table 1, also lists 'Hepatitis B surface antigen' as a required test during the 'Screening and PrEP initiation (visit 1)'.",yes,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Page 7, Table 2, under the row 'Hepatitis B surface antigen - negative', specifies the action as 'Offer Hepatitis B virus vaccination'.",no,Justification not provided,no,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Syphilis is mentioned as an example of a sexually transmissible infection that constitutes a behavioral risk factor on page 3, but there is no specific recommendation to screen for it. The document consistently refers to general 'STI testing' without specifying syphilis.",no,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Gonorrhoea is mentioned as an example of a sexually transmissible infection that constitutes a behavioral risk factor on page 3, but there is no specific recommendation to screen for it. The document consistently refers to general 'STI testing' without specifying gonorrhoea.",no,"Pakistan PrEP Guidelines Final 6.24.19 clean.pdf: Chlamydia is mentioned as an example of a sexually transmissible infection that constitutes a behavioral risk factor on page 3, but there is no specific recommendation to screen for it. The document consistently refers to general 'STI testing' without specifying chlamydia."
PAN,Panama,no,Justification not provided,yes,"Borrador guía PrEP producto 2GR - English.pdf: Page 16, bullet point under objective 3: 'Offer of tests for other sexually transmitted infections (syphilis, hepatitis B and C)'",no,Justification not provided,no,Justification not provided,yes,"Borrador guía PrEP producto 2GR - English.pdf: Page 16, bullet point under objective 3: 'Offer of tests for other sexually transmitted infections (syphilis, hepatitis B and C)' and Page 20, paragraph 2: 'For example, HIV and syphilis co-infection in MSM is high, so syphilis screening could be done at each follow-up visit.'",no,Justification not provided,no,Justification not provided
PRY,Paraguay,no,Justification not provided,yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'EXAMSREQUESTED AT THE FIRST CONSULTATION', lists 'Hepatitis B test' with the method 'HBsAg (e.g. rapid test) and anti-HBs research'.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 16, under 'Hepatitis B and C', states 'Vaccination for HBV is recommended for all people in any age group (three doses of the vaccine).'",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 8, Section 2.1 'COMBINED PREVENTION', item 8, lists 'Immunizations for HBV, HAV, HPV' as part of the comprehensive prevention package.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'EXAMSREQUESTED AT THE FIRST CONSULTATION', lists 'Syphilis test' with the method 'Syphilis test: rapid test and VDRL'.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'EXAMSREQUESTED AT THE FIRST CONSULTATION', lists 'Identification of other STIs (chlamydia and gonococcus)' with the method 'Anal swab, if available'.",yes,"manual de Profilaxis Pre exposicion del VIH ultimo - English.pdf: Page 13, Table 2, under 'EXAMSREQUESTED AT THE FIRST CONSULTATION', lists 'Identification of other STIs (chlamydia and gonococcus)' with the method 'Anal swab, if available'."
PHL,Philippines,ERR: yes (REF: no),"Prep guidelines 2021 approved philippines.pdf: Page 5, section E, item i, sub-item 1, point g, mentions discussing 'Intimate partner violence' during follow-up counseling.",yes,"Prep guidelines 2021 approved philippines.pdf: Page 3, Section C, item 2, point c: 'HBsAg test done within 30 days prior to PrEP initiation.'",yes,"Prep guidelines 2021 approved philippines.pdf: Page 3, Section C, item 2, point c, sub-point i: 'If the result is negative, recommend hepatitis B vaccination.'",no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided
POL,Poland,no,Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided
PRT,Portugal,no,Justification not provided,yes,"Portugal PrEP guideline .pdf: Page 3, point 3(j) recommends 'Avaliação do estado serológico para hepatite A, hepatite B, hepatite C e imunização ou tratamento quando indicado;' (Evaluation of the serological status for hepatitis A, hepatitis B, hepatitis C and immunization or treatment when indicated;).",yes,"Portugal PrEP guideline .pdf: Page 3, point 3(j) recommends 'Avaliação do estado serológico para hepatite A, hepatite B, hepatite C e imunização ou tratamento quando indicado;' (Evaluation of the serological status for hepatitis A, hepatitis B, hepatitis C and immunization or treatment when indicated;). 'Imunização' means immunization.",yes,"Portugal PrEP guideline .pdf: Page 3, point 3(k) recommends 'Avaliação da indicação de imunização para vírus do papiloma humano (HPV).' (Evaluation of the indication for immunization for human papillomavirus (HPV)).",yes,"Portugal PrEP guideline .pdf: Page 10, point G(3) states 'O rastreio de IST preconizado deverá incluir sífilis...' (The recommended STI screening should include syphilis...).",yes,"Portugal PrEP guideline .pdf: Page 10, point G(3) states 'O rastreio de IST preconizado deverá incluir ... Neisseria gonorrhoeae)' (The recommended STI screening should include ... Neisseria gonorrhoeae).",yes,"Portugal PrEP guideline .pdf: Page 10, point G(3) states 'O rastreio de IST preconizado deverá incluir ... infeção por Chlamydophila trachomatis...' (The recommended STI screening should include ... Chlamydophila trachomatis infection...)."
SLE,Sierra Leone,no,Justification not provided,yes,"Sierre Leone_Consolidated_HIV_Guidelines_.pdf: Page 55, under the section 'Screening for PrEP eligibility', the document states to 'Assess for hepatitis B infection'.",no,Justification not provided,no,Justification not provided,no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: The document mentions evaluating for 'symptoms of STI s' (Page 55) in the PrEP section but does not specifically recommend screening for syphilis.,no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: The document mentions evaluating for 'symptoms of STI s' (Page 55) in the PrEP section but does not specifically recommend screening for Neisseria gonorrhoeae.,no,Sierre Leone_Consolidated_HIV_Guidelines_.pdf: The document mentions evaluating for 'symptoms of STI s' (Page 55) in the PrEP section but does not specifically recommend screening for Chlamydia trachomatis.
SGP,Singapore,no,Justification not provided,yes,"NHIVP PrEP Guidance_2019.pdf: Page 11, Table IV, under the row 'Hepatitis B screening', the 'Example' column lists 'Hepatitis B surface antigen (HBsAg) and antibody (anti-HBs)'.",yes,"NHIVP PrEP Guidance_2019.pdf: Page 11, Table IV, under the row 'Hepatitis B screening', the 'Additional Considerations' column states 'Vaccination against hepatitis B should be offered to non-immune individuals.'.",yes,"NHIVP PrEP Guidance_2019.pdf: Page 12, Table IV, under the row 'Other services', the 'Example' column lists 'Vaccination against hepatitis A, B and human papillomavirus as indicated'.",yes,"NHIVP PrEP Guidance_2019.pdf: Page 11, Table IV, lists 'Syphilis screening' as an action to be done at the first consultation.",yes,"NHIVP PrEP Guidance_2019.pdf: Page 14, Table V, under the row 'STI screening and treatment', the 'Additional Considerations' column lists 'Syphilis, gonorrhoea and chlamydia screening 3 – 6 monthly'.",yes,"NHIVP PrEP Guidance_2019.pdf: Page 14, Table V, under the row 'STI screening and treatment', the 'Additional Considerations' column lists 'Syphilis, gonorrhoea and chlamydia screening 3 – 6 monthly'."
SVK,Slovak Republic,no,"SVK PrEP Guidelines ENG.pdf: The document discusses assessing a patient's risk based on their partners' HIV status or risk behaviors (Page 7, Page 16) but does not mention services for testing, treating, or managing partners for STIs other than HIV.",yes,"SVK PrEP Guidelines ENG.pdf: Page 14, Hepatitis B infection: ""This includes testing for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc) and hepatitis B surface antibodies (anti-HBs).""",yes,"SVK PrEP Guidelines ENG.pdf: Page 14, Hepatitis B infection: ""Persons with no signs of prior infection (i.e., Anti-HBs, anti-HBc, HBsAg- negative) should be vaccinated against HBV, as individuals who engage in high-risk sexual behavior and drug use are at increased risk of acquiring hepatitis B.""",no,SVK PrEP Guidelines ENG.pdf: The document does not mention Human Papillomavirus (HPV) or HPV vaccination.,yes,"SVK PrEP Guidelines ENG.pdf: Page 8, STI screening: ""STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3).""",yes,"SVK PrEP Guidelines ENG.pdf: Page 8, STI screening: ""STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3).""",yes,"SVK PrEP Guidelines ENG.pdf: Page 8, STI screening: ""STI screening should include serological tests for syphilis and nucleic acid amplification tests for gonorrhea and chlamydia from relevant mucous membranes (Table 3)."""
ZAF,South Africa,no,"South African Guidelines for Provision of PrEP.pdf: The document mentions 'Voluntary partner HIV testing and treatment' (Page 10) and encouraging partners to test for HIV (Page 17), but does not specify partner management for other STIs.",yes,"South African Guidelines for Provision of PrEP.pdf: Page 12, Table 1, under 'Baseline Investigation performed prior to initiating a client on PrEP', lists screening for 'Hepatitis B surface antigen (HBsAg)' as a required investigation.",yes,"South African Guidelines for Provision of PrEP.pdf: Page 12, Table 1, specifies the action for a negative HBsAg test result is to 'start PrEP and vaccinate, if available'.",no,South African Guidelines for Provision of PrEP.pdf: The document does not mention Human Papillomavirus (HPV) or HPV vaccination.,no,"South African Guidelines for Provision of PrEP.pdf: The document recommends 'Syndromic STI diagnosis and treatment' and 'STI screening' (Pages 10, 12, 16) but does not specifically mention screening for syphilis or Treponema pallidum.",no,"South African Guidelines for Provision of PrEP.pdf: The document recommends 'Syndromic STI diagnosis and treatment' and 'STI screening' (Pages 10, 12, 16) but does not specifically mention screening for Neisseria gonorrhoeae.",no,"South African Guidelines for Provision of PrEP.pdf: The document recommends 'Syndromic STI diagnosis and treatment' and 'STI screening' (Pages 10, 12, 16) but does not specifically mention screening for Chlamydia trachomatis."
SSD,South Sudan,no,Justification not provided,yes,"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 30, Section: PrEP minimum package: 'The PrEP minimum Package of services include: ... Hepatitis screening'.",no,Justification not provided,no,Justification not provided,ERR: yes (REF: no),"S. Sudan HIV Consolidated ART Guidelines_10 Sept 2021 2332hrs[6223]RS.pdf: Page 34, Figure 9.2 Algorithm for PrEP among pregnant and breastfeeding women: In a box titled 'Provide comprehensive HIV prevention options', it lists '1. STI screening and treatment (syndromic and syphilis)'.",no,Justification not provided,no,Justification not provided
ESP,Spain,no,Justification not provided,yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, Section 6.c recommends Hepatitis B serology before starting PrEP: 'HBV: Vaccination is recommended if serology is negative or antibody levels are below the limit of protection.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, Section 6.c recommends vaccination for Hepatitis B if serology is negative. Also, Page 10, Table 1 lists 'vaccination HAV, HBV and HPV' as a biomedical strategy combined with PrEP.",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 10, Table 1 lists 'vaccination HAV, HBV and HPV' as a biomedical strategy combined with PrEP.",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, Section 6.b states, 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, Section 6.b states, 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.'",yes,"Spain_PROFILAXIS_PREEXPOSICION_VIH.es.en.PDF: Page 28, Section 6.b states, 'STI screening: should include gonococcus, chlamydia, syphilis, in all people, even if they are asymptomatic.'"
SWE,Sweden,no,Justification not provided,yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, Fact box 1, Before starting treatment, Sampling: ""Hepatitis B serology (exclusion of chronic carriers)""",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, Fact box 1, Before starting treatment, Vaccination: ""Offer hepatitis B vaccination to anyone who lacks protection""",no,Justification not provided,yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, Fact box 1, Before starting treatment, Sampling: ""syphilis serology"". And under Follow-up, Thereafter every 3 months: ""Sampling for chlamydia, gonorrhea, syphilis"".",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, Fact box 1, Before starting treatment, Sampling: ""Chlamydia and gonorrhea from all premises, syphilis serology"". And under Follow-up, Thereafter every 3 months: ""Sampling for chlamydia, gonorrhea, syphilis"".",yes,"Sweden_hiv_prep_2017_v170824.sv.en.pdf: Page 3, Fact box 1, Before starting treatment, Sampling: ""Chlamydia and gonorrhea from all premises, syphilis serology"". And under Follow-up, Thereafter every 3 months: ""Sampling for chlamydia, gonorrhea, syphilis""."
CHE,Switzerland,no,Justification not provided,yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, in the 'Procedure in practice' box, under 'Before PrEP is prescribed': 'Exclusion of hepatitis B infection based on HBsAg and ALT...'",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, in the 'Procedure in practice' box, under 'Before PrEP is prescribed': 'Hepatitis A and B vaccination if the patient is not immune'.",no,Justification not provided,yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, in the 'Procedure in practice' box, under 'Before PrEP is prescribed': 'Additional laboratory investigations: serology tests for hepatitis A, B and C, and syphilis'. And under 'Every 3 months': 'Syphilis serology'.",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, in the 'Procedure in practice' box, under 'Before PrEP is prescribed': 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'.",yes,"fcsh-recommendations-prep-hiv (1).pdf: Page 2, in the 'Procedure in practice' box, under 'Before PrEP is prescribed': 'Anal, oral and urethral (vaginal) smears for C. trachomatis and N. gonorrhoeae'."
TJK,Tajikistan,no,Justification not provided,yes,"TJK PrEP Guidelines ENG.pdf: Page 14: ""It is also recommended to test individuals receiving PrEP for hepatitis B virus surface antigen (HBsAg).""",yes,"TJK PrEP Guidelines ENG.pdf: Page 14: ""In cases where HBsAg is not detected and there is no information about vaccination in the past, clients are advised to vaccination against hepatitis B"".",no,Justification not provided,no,Justification not provided,no,Justification not provided,no,Justification not provided
THA,Thailand,ERR: no (REF: yes),Justification not provided,yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1, 'Laboratory examination' row states: ""hepatitis B at Month 0"". The 'Minimum laboratory examination' row also specifies: ""Monitoring of hepatitis B (HBsAg, only those who have not yet acquired immunity)"".",ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1, 'Laboratory examination' row lists ""Syphilis... at Month 0, every 3-6 months"".",yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1, 'Laboratory examination' row lists ""gonorrhea... at Month 0, every 3-6 months"".",yes,"thailand_national_guidelines_for_pre-exposure_prophylaxis_prep_2021_chapters_1-2.pdf: Page 13, Table 1.1, 'Laboratory examination' row lists ""chlamydia, at Month 0, every 3-6 months""."
GBR,United Kingdom,no,Justification not provided,yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 24: 'We recommend that baseline screening for hepatitis B should be undertaken in those of unknown hepatitis B status to exclude active hepatitis B infection...'",yes,"2018-PrEP-Guidelines.pdf: Page 12, Recommendation 24: '...with vaccination initiated in those who are non-immune. (1A)'",no,Justification not provided,yes,"2018-PrEP-Guidelines.pdf: Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis) in all taking PrEP...'",yes,"2018-PrEP-Guidelines.pdf: Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis) in all taking PrEP...'",yes,"2018-PrEP-Guidelines.pdf: Page 13, Recommendation 40: 'We recommend 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis) in all taking PrEP...'"
USA,United States,yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 33 states, ""Heterosexually-active men and women being evaluated for, or being prescribed PrEP, in whom gonorrhea or chlamydia infection is detected, should be offered expedited partner therapy (EPT),"" and ""Patients with syphilis or HIV diagnosed should be referred for partner services.""",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 34 states, ""Ideally, prior to prescribing PrEP, patients should be screened for HBV (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf) so that in the event they have HBV infection, they can be informed of the danger of stopping PrEP medication without appropriate monitoring for potential hepatitis flares."" Table 5 on page 44 also lists ""Hep B serology"" under the ""Screening/Baseline Visit"" column.",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 35 states, ""Patients who are not immune and do not have HBV infection should be vaccinated."" Table 8 on page 63 also recommends Hepatitis B vaccine for all risk groups.",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Table 8 on page 63, under ""Primary Care Health Measures,"" recommends the ""HPV vaccine"" for MSM, MSW, Women, and PWID through age 26.",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 32 states, ""Tests to screen for syphilis are recommended for all adults prescribed PrEP, both at screening and at semi-annual visits."" Table 5 on page 44 also lists syphilis screening at baseline and follow-up.",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 32 states, ""Tests to screen for gonorrhea are recommended for all sexually active adults prescribed PrEP, both at screening, for MSM at quarterly visits, and for women at semi-annual visits."" Table 5 on page 44 also lists gonorrhea screening at baseline and follow-up.",yes,"PrEPguideline2021_PublicCommentDraft.pdf: Page 32 states, ""Tests to screen for chlamydia are recommended for all sexually active MSM prescribed PrEP, both at screening prior to initiation and at quarterly visits."" It also mentions that ""screening for chlamydia is recommended at initiation and every 12 months for all sexually active women as a component of PrEP care."" Table 5 on page 44 also lists chlamydia screening at baseline and follow-up."
UGA,Uganda,no,Justification not provided,yes,"consolidated_guidelines_hiv_prevention_uganda.pdf: Page 31, Table 8, Screening for PrEP eligibility: 'Assess for hepatitis B infection: if negative, patient is eligible for PrEP; if positive, refer patient for management'.",no,Justification not provided,no,Justification not provided,no,"consolidated_guidelines_hiv_prevention_uganda.pdf: The document recommends evaluating for STI symptoms syndromically ('Evaluate the patient for any symptoms of STIs at every visit and treat as needed' - Page 31, Table 8), but does not specify screening for syphilis pathogen for PrEP users.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: The document recommends evaluating for STI symptoms syndromically ('Evaluate the patient for any symptoms of STIs at every visit and treat as needed' - Page 31, Table 8), but does not specify screening for Neisseria gonorrhoeae for PrEP users.",no,"consolidated_guidelines_hiv_prevention_uganda.pdf: The document recommends evaluating for STI symptoms syndromically ('Evaluate the patient for any symptoms of STIs at every visit and treat as needed' - Page 31, Table 8), but does not specify screening for Chlamydia trachomatis for PrEP users."
UKR,Ukraine,ERR: yes (REF: no),"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 2, item h) under 'Counseling people before prescribing PrEP consists of informing and examining to identify contraindications:' states 'h) assessment of the risk of intimate partner violence;'",yes,"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 1, under 'List of examinations before prescribing PrEP Mandatory:', a bullet point states 'HBV screening: HBsAg** People who test positive for HBsAg are recommended to take PrEP on a daily regimen.'",yes,"UKR HIV Guidelines - Annex 4 ENG.pdf: Page 1, under 'Coveted:', a bullet point states 'In the absence of HBV markers, vaccination is offered.'",no,Justification not provided,ERR: no (REF: yes),Justification not provided,no,Justification not provided,no,Justification not provided
URY,Uruguay,no,Justification not provided,yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 12, in Table 8 'Componentes paraclínicos', lists 'Hepatitis B' under 'Examen' and 'HBsAg, HBsAc, HbcAc' under 'Método'.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 4 states: 'Asimismo, se deben revisar la historia de vacunas de virus de hepatitis B (VHB)... e indicarlas según la situación.' (Furthermore, the history of hepatitis B virus (HBV) vaccines... should be reviewed and indicated according to the situation.). Page 9 also lists 'Indicación de vacunación de VHB... según corresponda' (Indication for HBV vaccination... as appropriate).",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 4 states: 'Asimismo, se deben revisar la historia de vacunas de... virus del papiloma humano (HPV) e indicarlas según la situación.' (Furthermore, the history of... human papillomavirus (HPV) vaccines should be reviewed and indicated according to the situation.). Page 9 also lists 'Indicación de vacunación de... VPH según corresponda' (Indication for... HPV vaccination as appropriate).",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 12, in Table 8 'Componentes paraclínicos', lists 'Sífilis' under 'Examen' and recommends a rapid test or VDRL/RPR.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 12, in Table 8 'Componentes paraclínicos', lists 'Chlamydia y gonococo' under 'Examen'. 'Gonococo' refers to Neisseria gonorrhoeae.",yes,"Guia_PreProfilaxis_VIH_Uruguay_2020.pdf: Page 12, in Table 8 'Componentes paraclínicos', lists 'Chlamydia y gonococo' under 'Examen'."
UZB,Uzbekistan,no,Justification not provided,yes,"UZB PrEP Guidelines ENG.pdf: Page 6, table, row 'Hepatitis B testing': 'A study on HBsAg is necessary.'",yes,"UZB PrEP Guidelines ENG.pdf: Page 6, table, row 'Hepatitis B testing': 'Deciding whether to vaccinate against Hepatitis B in the absence of antibodies to HBsAg'",no,Justification not provided,yes,"UZB PrEP Guidelines ENG.pdf: Page 6, table, row 'STI test': '...serological examination for syphilis.' and Page 7, table, row 'Serological studies for hepatitis B and C, syphilis': 'Every 6 months'",no,Justification not provided,no,Justification not provided
VNM,Vietnam,no,Justification not provided,yes,"Vietnam National Guidelines for HIV 2017 _EN.pdf: Page 41, Section 10.2, Step 5: 'Perform creatinine test and HbsAg test'.",ERR: no (REF: yes),Justification not provided,no,Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided,ERR: no (REF: yes),Justification not provided
ZMB,Zambia,no,Justification not provided,ERR: no (REF: yes),Justification not provided,no,Justification not provided,no,Justification not provided,ERR: no (REF: yes),Justification not provided,no,Justification not provided,no,Justification not provided
ZWE,Zimbabwe,no,Justification not provided,yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: Recommends testing for Hepatitis B surface antigen (HBsAg) at baseline, if available.",yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: In the rationale for HBsAg testing, it states ""If negative, consider vaccination against hepatitis B.""",no,Justification not provided,yes,"Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: Page 27, Table 5: Recommends a Rapid Syphilis Test at baseline if available.",no,Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: The document mentions syndromic STI management but does not specifically recommend screening for Neisseria gonorrhoeae.,no,Implementation plan for HIV PrEP in Zimbabwe 2018-2020.pdf: The document mentions syndromic STI management but does not specifically recommend screening for Chlamydia trachomatis.
